Cangrelor

CHEMBL334966 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

776.4 g/mol

LogP

-1.0

Phase

4

A short-acting intravenous antiplatelet drug that rapidly inhibits the P2Y12 receptor to prevent platelet aggregation during and after heart procedures such as percutaneous coronary intervention. Its very short half-life allows quick reversal of antiplatelet effects, which is useful when bridging to oral therapy. It is used in patients who have not been pre-treated with oral P2Y12 inhibitors.

Masse moléculaire

776,4000 g/mol

LogP

-1,00

TPSA

307,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Systemic Lupus Erythematosus Stroke

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O

InChI

InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1

Molecular Formula

C17H25Cl2F3N5O12P3S2

HBD / HBA

7 / 21

Liaisons Rotatives

15

Atomes Lourds

44

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A short-acting intravenous antiplatelet drug that rapidly inhibits the P2Y12 receptor to prevent platelet aggregation during and after heart procedures such as percutaneous coronary intervention. Its very short half-life allows quick reversal of antiplatelet effects, which is useful when bridging to oral therapy. It is used in patients who have not been pre-treated with oral P2Y12 inhibitors.

Yes, Cangrelor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL334966. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9854012. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Cangrelor sur PillFYI

Structure

Données Clés

Formule: C17H25Cl2F3N5O12P3S2
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.